A Clinical Assessment of Glass Carbomer Cement
Launched by KING ABDULAZIZ UNIVERSITY · Jan 21, 2017
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
Glass Carbomer is a monomer free; carbomised nano-glass restorative cement developed from traditional glass ionomer cement (GIC) and contains nano-sized powder particles of hydroxyapatite and fluorapatite. These materials claim to have improved mechanical properties and better bonding to dentin, in addition to continues fluoride release.
The study is a randomized controlled clinical trial where teeth will be randomly assigned to one of the three restoration groups.
Following medical and dental history, bilateral bitewing radiographs will be taken for each patient to assess the presence of...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • One proximal lesion in a primary molar.
- • Radiographic evidence of caries extending at least into the inner half of the enamel but not the inner half of dentin.
- • Proximal contact with adjacent healthy or restored teeth.
- • Occlusal contact with opposing healthy or restored teeth.
- • No indication for pulp therapy or other restorative treatment.
- • A predicted survival until exfoliation of 2 years.
- Exclusion Criteria:
- • Radiographic evidence of caries extending into the inner half of dentin.
- • No proximal contact with adjacent healthy or restored teeth.
- • No occlusal contact with opposing healthy or restored teeth.
- • Tooth indicated for pulp therapy or other restorative treatment.
- • A predicted survival until exfoliation of less than 2 years.
About King Abdulaziz University
King Abdulaziz University (KAU) is a leading academic institution located in Jeddah, Saudi Arabia, renowned for its commitment to advancing medical research and innovation. As a prominent clinical trial sponsor, KAU leverages its extensive resources and expertise to facilitate groundbreaking studies aimed at improving healthcare outcomes. The university fosters collaboration among multidisciplinary teams of researchers, clinicians, and industry partners, ensuring adherence to rigorous ethical standards and regulatory requirements. KAU is dedicated to enhancing scientific knowledge and translating research findings into practical applications that benefit patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Najlaa Alamoudi, MSc, DSc
Study Chair
King Abdulaziz University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials